Comprehensive analysis of FDA facility inspections — OAI, VAI, and NAI
classification outcomes, most-inspected companies, geographic distribution,
product types, and FDA center activity. Sourced from official FDA databases. Data Sources below shows when each was last refreshed.
When each FDA source behind these statistics was last refreshed
Records
Last refreshed
Source as of
Status
Inspections (FDA Data Dashboard)
Nov 16, 2026
Newest record Nov 5, 2026
Current
Inspections by Classification (OAI / VAI / NAI)
Classification
Inspections
No Action Indicated
179,613
Voluntary Action Indicated
88,372
Official Action Indicated
10,563
Yearly Trends & Classification Breakdown
Fiscal year
Inspections
OAI
VAI
NAI
FY2027 to date
356
2
70
284
FY2026
14,878
336
3,851
10,691
FY2025
15,780
604
4,622
10,554
FY2024
13,823
520
4,020
9,283
FY2023
14,531
456
4,380
9,695
FY2022
12,025
479
3,676
7,870
FY2021
6,895
349
2,445
4,101
FY2020
7,980
280
2,845
4,855
FY2019
16,357
500
5,253
10,604
FY2018
17,900
433
5,601
11,866
FY2017
17,882
597
5,404
11,881
FY2016
17,146
620
5,340
11,186
FY2015
16,673
780
5,432
10,461
FY2014
16,629
760
5,509
10,360
FY2013
17,432
869
5,401
11,162
FY2012
19,959
845
6,413
12,701
FY2011
20,094
862
7,010
12,222
FY2010
17,580
701
6,180
10,699
FY2009
14,628
570
4,920
9,138
Top Inspected Companies
Company
Inspections
Delta Air Lines
1,106
Biomat Usa
903
Vitalant
830
American National Red Cross
815
Boeing Commercial Airplane
752
Csl Plasma
687
Oneblood
679
Southwest Airlines
528
American Airlines
520
Airgas Usa
481
Bimbo Bakeries Usa
438
Octapharma Plasma
344
United Airlines
332
Darling Ingredients
285
Envoy Air
248
Spirit Airlines
240
Frontier Airlines
225
American National Red Cross (The)
197
Biolife Plasma Services L.P
191
Gate Gourmet
189
Geographic Distribution
State
Inspections
California
31,637
Texas
14,932
New York
13,802
Florida
13,747
Pennsylvania
10,299
New Jersey
9,581
Wisconsin
9,272
Illinois
8,542
Minnesota
8,050
Ohio
7,902
Washington
7,192
Massachusetts
6,136
Michigan
5,720
Georgia
5,549
Missouri
5,062
Product Type Breakdown
Product type
Inspections
Food/Cosmetics
156,024
Drugs
37,408
Devices
32,550
Biologics
27,662
Veterinary
23,579
Tobacco
1,325
FDA Center Breakdown
Project area
Inspections
Foodborne Biological Hazards
120,806
Drug Quality Assurance
24,637
Monitoring of Marketed Animal Drugs, Feed, and Devices
22,863
Bioresearch Monitoring
18,790
Compliance: Devices
18,785
Blood and Blood Products
16,862
Food Composition, Standards, Labeling and Econ
16,156
Technical Assistance: Food and Cosmetics
13,598
Postmarket Assurance: Devices
8,133
Human Cellular, Tissue, and Gene Therapies
7,690
Pesticides and Chemical Contaminants
2,619
Food and Color Additives Petition Review
1,775
Vaccines and Allergenic Products
1,294
Tobacco Post-Market Activities
1,289
Colors and Cosmetics Technology
1,036
Radiation Control and Health Safety Act
930
Project Evaluation: Devices
517
Unapproved and Misbranded Drugs
349
Pre-Approval Eval. of Animal Drugs and Food Additives
312
Postmarket Surv. and Epidemiology
46
Tobacco Pre-Market Activities
23
Molecular Biology and Natural Toxins
23
Over-the-Counter Drug Evaluation
12
Prescription Drug Advertising and Labelling
3
Loading inspection statistics…
—
Total FDA Inspections
—
OAI Rate (Most Severe)
—
Latest Fiscal Year
Overview
A high-level snapshot of FDA facility inspection activity across all classifications,
product types, and FDA centers.
Inspections by Classification (OAI / VAI / NAI)
After an inspection, the FDA assigns a classification outcome.
OAI (Official Action Indicated) means regulatory
and/or administrative actions are recommended. An OAI classification alone is not evidence that a
Warning Letter, import alert, or court action followed; any such action is a separate record.
VAI (Voluntary Action Indicated) means objectionable conditions or practices were
found, but the agency is not prepared to take or recommend any administrative or regulatory action.
NAI (No Action Indicated) means no objectionable conditions or practices were found during the inspection.
Show data table
Classification
Description
Inspections
Yearly Trends & Classification Breakdown
Annual inspection counts by fiscal year with OAI/VAI/NAI classification stacked breakdown,
showing trends in FDA enforcement activity over time.
Show data table
Fiscal Year
OAI
VAI
NAI
Total
Top Inspected Companies
The 20 most frequently inspected companies by the FDA, based on normalized legal entity names.
High inspection counts may reflect large facility footprints, regulatory history, or product scope.
#
Company
Inspections
Geographic Distribution
Top 15 U.S. states by number of FDA inspections. Concentration tends to correlate
with states that have large pharmaceutical manufacturing, medical device, and food production sectors.
Show data table
#
State
Inspections
Product Type Breakdown
FDA inspections span multiple product categories including drugs, biologics, devices,
food/cosmetics, veterinary products, and more.
Show data table
Product Type
Inspections
FDA Center Breakdown
Inspections are conducted by different FDA centers:
CDER (drugs), CDRH (devices/radiological health),
CBER (biologics), CFSAN (food safety/nutrition),
CVM (veterinary medicine), and ORA (regulatory affairs).
FDA Center
Inspections
Frequently Asked Questions
How many FDA inspections are there per year?
Loading…
What do OAI, VAI, and NAI mean?
These are the three FDA inspection classification outcomes.
OAI (Official Action Indicated) means regulatory and/or administrative
actions are recommended. An OAI classification on its own is not evidence that a Warning
Letter, import alert, or court action followed — any such action is recorded separately.
VAI (Voluntary Action Indicated) means objectionable conditions or practices
were found, but the agency is not prepared to take or recommend any administrative or
regulatory action. NAI (No Action Indicated)
means no objectionable conditions or practices were found during the inspection.
Which companies are inspected most by the FDA?
Loading…
What triggers an FDA inspection?
FDA inspections can be triggered by several factors: routine surveillance schedules
(the FDA inspects domestic drug manufacturers every 2 years on average), pre-approval
inspections for new drug or device applications, for-cause inspections prompted by
adverse event reports or complaints, follow-up inspections after previous OAI or
VAI findings, compliance follow-ups to Warning Letters, and import inspections at
ports of entry. The FDA uses a risk-based approach to prioritize which facilities
to inspect.
Access FDA inspections plus the broader MCP toolset for warning letters,
import risk, facilities, and product intelligence. Start free with 50 credits at signup,
then 300 credits a month after you verify your email.
Source: RegDataLab, aggregating FDA Inspection Dashboard data.
Updated regularly from official FDA sources. This page pulls live data from our Postgres warehouse via the
/api/stats/inspections endpoint.